Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

NCT02568553 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

NIH

Sponsor class

Conditions

Recurrent Burkitt Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Grade 3a Follicular Lymphoma
Recurrent Grade 3b Follicular Lymphoma
Recurrent Gray-Zone Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Mediastinal Lymphoma
Recurrent Non-Hodgkin Lymphoma
Recurrent Small Lymphocytic Lymphoma
Refractory Burkitt Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Follicular Lymphoma
Refractory Grade 1 Follicular Lymphoma
Refractory Grade 2 Follicular Lymphoma
Refractory Grade 3 Follicular Lymphoma
Refractory Grade 3a Follicular Lymphoma
Refractory Gray-Zone Lymphoma
Refractory Mantle Cell Lymphoma
Refractory Marginal Zone Lymphoma
Refractory Mediastinal Lymphoma
Refractory Non-Hodgkin Lymphoma
Refractory Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: Blinatumomab
DRUG: Lenalidomide

Sponsor

National Cancer Institute (NCI)